HIFU focal therapy for prostate cancer using intraoperatory contrast enhanced ultrasound.

Autor:	Claros OR; Institut Mutualiste Montsouris. Paris. France. Hospital Israelita Albert Einstein. São Paulo. Brazil., Tourinho-Barbosa RR; Institut Mutualiste Montsouris. Paris. France. Hospital Cardiopulmonar. Bahia. Brazil., Carneiro A; Hospital Israelita Albert Einstein. São Paulo. Brazil., Collura-Merlier S; Institut Mutualiste Montsouris. Paris. France. Hospital Ángeles del Pedregal. Mexico., Macek P; Institut Mutualiste Montsouris. Paris. France., Lanz C; Institut Mutualiste Montsouris. Paris. France., Cathala N; Institut Mutualiste Montsouris. Paris. France., Prapotnich D; Institut Mutualiste Montsouris. Paris. France., Mombet A; Institut Mutualiste Montsouris. Paris. France., Sanchez-Salas R; Institut Mutualiste Montsouris. Paris. France., Cathelineau X; Institut Mutualiste Montsouris. Paris. France.
Jazyk:	angličtina
Zdroj:	Archivos espanoles de urologia [Arch Esp Urol] 2019 Oct; Vol. 72 (8), pp. 825-830.
Abstrakt:	Objective: High-intensity focused ultrasound (HIFU) Focal therapy appears to have encouraging oncologic outcomes and urinary and erectile function. The control of the treated area can be done using contrast enhanced ultrasound with sulfur hexafluoride (Sonovue®) at the end of the procedure. We report oncological and functional outcomes in HIFU focal therapy (FT) for prostate cancer (PCa) management using sonovue. Methods: A total of 274 HIFU procedures were found in our registry in the period between June 2014 and July 2018. Prospective data of 59 consecutive patients after focal high-intensity focused ultrasound (HIFU) using Sonovue were collected. FT failure was defined as positive biopsy Gleason score (GS) ≥ 7 in- or out-field, local or systemic salvage treatment, PCa-metastasis or PCa-specific death. Results: A total of 59 patients submitted to HIFU with median follow-up of 18 months were included in the analysis. Median age was 66.7 yr (IQR 59.1-74.3). Median preoperative prostate-specific antigen (PSA) was 7.6 ng/ml (IQR 5-10.2) and preoperative biopsies GS 6, 7(3+4), 7(4+3) were found in 26 (44%), 30 (50.8%) and 3 (5%), respectively. Failure was found in 16 (27.1%) patients. Failure-free survival (FFS) in 2 and 4yr was 83% and 74% respectively (Figure 1). No PCa-specific death was registered in the period of study. Median nadir PSA after FT was 2.67 ng/ml. Sexual potency was achieved in 75% of previous potent patients and urinary continence in 93.4% of patients at 3 months. Fourteen (23%) patients presented with complications. Four (6.7%) patients have presented complications grade 1 and 10 (16.9%) patients have presented complications grade 2. Six (10.1%) patients have presented acute urinary retention. Conclusions: Our study shows that the use of Sonovue after HIFU FT was safe. Patients present a significant proportion of failure after HIFU FT but with good functional outcomes and without incidence of severe complications.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu